Japan Tissue Engineering Full Year 2025 Earnings: JP¥6.28 loss per share (vs JP¥3.52 profit in FY 2024)
Japan Tissue Engineering (TSE:7774) Full Year 2025 Results
Key Financial Results
- Revenue: JP¥2.46b (down 2.3% from FY 2024).
- Net loss: JP¥255.0m (down by 278% from JP¥143.0m profit in FY 2024).
- JP¥6.28 loss per share (down from JP¥3.52 profit in FY 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Japan Tissue Engineering Earnings Insights
Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Japan.
Performance of the Japanese Biotechs industry.
The company's shares are down 1.1% from a week ago.
Risk Analysis
Be aware that Japan Tissue Engineering is showing 1 warning sign in our investment analysis that you should know about...
Valuation is complex, but we're here to simplify it.
Discover if Japan Tissue Engineering might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.